Reticulocyte

Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition

Retrieved on: 
Monday, December 11, 2023
Patient, Quality of life, Erythropoietin, Protein, Exposition, Fever, Reticulocyte, Homeostasis, Bone marrow, MF, IWG, Haematopoiesis, Research, Erythropoiesis, Diarrhea, Anemia, KROS, Fatigue, Nausea, Headache, RBC, Iron overload, Society, MDS, Therapy, Weakness, Ruxolitinib, Thrombocytopenia, ASH, TI, Week, Periodic breathing, MBBS, Biomarker, Safety, Acute myeloid leukemia, HTB, Cytopenia, Disorder, Pharmaceutical industry

“Additionally, we are encouraged by the preliminary data from the lowest three dose cohorts from our ongoing Phase 2 clinical trial in MF.

Key Points: 
  • “Additionally, we are encouraged by the preliminary data from the lowest three dose cohorts from our ongoing Phase 2 clinical trial in MF.
  • Data for hematological response and markers of hematopoiesis were presented from exploratory analyses of these mITT24 patients.
  • All data presented from this trial is as of the data cut-off date.
  • 13 of those 18 patients (72.2%) achieved TI for at least 24 weeks over the first 48 weeks of treatment.

NovelMed Commences Phase II Trial for Anti-Bb Antibody (NM8074) in Treatment-Naïve PNH Patients: A Glimpse into the PNH Study Progress

Retrieved on: 
Monday, October 30, 2023
FDA, CP, PNH, Hemolysis, C3b, LDH, Intravascular hemolysis, Phase, Phase II, EVH, Lactate dehydrogenase, RBC, Risk, Paroxysmal nocturnal hemoglobinuria, AP, Safety, IVH, Therapy, Patient, Infection, PRBC, Pharmaceutical industry, Haptoglobin, Hemoglobin, Reticulocyte

Regulatory approval for the Phase II trial in treatment-naïve PNH patients was granted based on the safety and tolerance demonstrated in the previous Phase I clinical trial involving healthy subjects.

Key Points: 
  • Regulatory approval for the Phase II trial in treatment-naïve PNH patients was granted based on the safety and tolerance demonstrated in the previous Phase I clinical trial involving healthy subjects.
  • CLEVELAND, Oct. 30, 2023 (GLOBE NEWSWIRE) -- NovelMed Therapeutics is excited to announce the commencement of its Phase II clinical trial targeting treatment-naïve Paroxysmal Nocturnal Hemoglobinuria (PNH) patients with its groundbreaking anti-Bb antibody, NM8074.
  • This open-label, multi-dose, and multi-center study aims to assess the safety and efficacy of NM8074 in PNH patient population.
  • The Phase II study is divided into two cohorts, featuring a biweekly dosing schedule spanning a 3-month assessment period.

World Hematology and Coagulation Market Research Report 2023: A Nearly $10 Billion-Dollar Market - Demand for Decentralized Testing, New Technologies and Aging Populations Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 6, 2023
Health, Biotechnology, Platelet, Hematocrit, Stroke, Decentralization, Segment, Enzyme, Ageing, Artery, Cell, Fibrinolysis, Government, Literature, Protein, Bone marrow, PTT, Hemostasis, CBC, Laboratory, Country Markets, Blood, Anemia, IVD, Reticulocyte, Automation, Cryptocurrency, Microscope, Birth control, Renewable energy, Coagulation, Hematology

There is a nearly $10 billion-dollar market for hematology and coagulation IVD testing.

Key Points: 
  • There is a nearly $10 billion-dollar market for hematology and coagulation IVD testing.
  • Increasingly growth is driven by new technologies, the aging population, and the demand for decentralized testing.
  • The basis of hematology testing is the complete blood count (CBC) that provides information on blood components: hemoglobin, hematocrit, red blood cells, white blood cells, reticulocytes, and platelets.
  • The CBC is run as part of the normal work up in an annual health exam and for every inpatient.

Carcell welcomes Prof. Harvey Lodish as Chair of its Scientific Advisory Board

Retrieved on: 
Monday, December 19, 2022
Sanofi, Nobel Prize, European, Coronavirus Scientific Advisory Board (Turkey), Cell, Assistant, RBC, Whitehead Institute, Chemistry, Degenerative disease, National academy, National university, Student, American Association for Cancer Research, Takeda, Reticulocyte, Investment, MIT, Physiology, Stem cell, Cancer, Brown University, Genzyme, European Molecular Biology Organization, Knowledge, Multimedia, Massachusetts Institute of Technology, Biological engineering, Cell biology, American Academy, National University of Singapore, National Center for Advancing Translational Sciences, Research, Biomedical Research, Red blood cell, Takeda Oncology, Patient, Therapy, Medical device, Pharmaceutical industry, Science, Biology, Medicine, Yves Carcelle

SINGAPORE and SHANGHAI, Dec. 19, 2022 /PRNewswire/ -- Carcell Biopharma ("Carcell"), an EVX Ventures company, is pleased to announce Prof. Harvey Lodish as the Chair of the Scientific Advisory Board.

Key Points: 
  • SINGAPORE and SHANGHAI, Dec. 19, 2022 /PRNewswire/ -- Carcell Biopharma ("Carcell"), an EVX Ventures company, is pleased to announce Prof. Harvey Lodish as the Chair of the Scientific Advisory Board.
  • He joins Prof. Jianzhu Chen of the Massachusetts Institute of Technology (MIT) and Dr. Hagop Youssoufian of Brown University on Carcell's Scientific Advisory Board to propel scientific advancement of its cell and gene therapy platforms.
  • Prof. Lodish brings onboard decades of experience in biotech and especially red blood cell (RBC)-based therapeutics to the team.
  • XQ Lin, the Chairman of Carcell, commented, "We are delighted to have Prof. Lodish join us as the Chair of our Scientific Advisory Board.

Carcell welcomes Prof. Harvey Lodish as Chair of its Scientific Advisory Board

Retrieved on: 
Monday, December 19, 2022
Sanofi, Nobel Prize, European, Coronavirus Scientific Advisory Board (Turkey), Cell, Assistant, RBC, Whitehead Institute, Chemistry, Degenerative disease, National academy, National university, Student, American Association for Cancer Research, Takeda, Reticulocyte, Investment, MIT, Physiology, Stem cell, Cancer, Brown University, Genzyme, European Molecular Biology Organization, Knowledge, Massachusetts Institute of Technology, Biological engineering, Cell biology, American Academy, National University of Singapore, National Center for Advancing Translational Sciences, Research, Biomedical Research, Red blood cell, Takeda Oncology, Patient, Therapy, Medical device, Pharmaceutical industry, Science, Biology, Medicine, Yves Carcelle

SINGAPORE and SHANGHAI, Dec. 19, 2022 /PRNewswire/ -- Carcell Biopharma ("Carcell"), an EVX Ventures company, is pleased to announce Prof. Harvey Lodish as the Chair of the Scientific Advisory Board.

Key Points: 
  • SINGAPORE and SHANGHAI, Dec. 19, 2022 /PRNewswire/ -- Carcell Biopharma ("Carcell"), an EVX Ventures company, is pleased to announce Prof. Harvey Lodish as the Chair of the Scientific Advisory Board.
  • He joins Prof. Jianzhu Chen of the Massachusetts Institute of Technology (MIT) and Dr. Hagop Youssoufian of Brown University on Carcell's Scientific Advisory Board to propel scientific advancement of its cell and gene therapy platforms.
  • Prof. Lodish brings onboard decades of experience in biotech and especially red blood cell (RBC)-based therapeutics to the team.
  • XQ Lin, the Chairman of Carcell, commented, "We are delighted to have Prof. Lodish join us as the Chair of our Scientific Advisory Board.

Vincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022

Retrieved on: 
Sunday, December 11, 2022
Enzyme, Flow cytometry, WBC, Primate, ASH, AML, Hematocrit, Toxicity, COVID-19, Basophil, Observation, Bilirubin, Form 10-K, Gemstone, NHP, Reticulocyte, Safety, Cancer, Antibody-drug conjugate, CD123, Workforce, Biosimilar, Society, Pandemic, Hematology, Therapy, Diffusion, ADC, Control, Venetoclax, Male, PALO, Patient, Azacitidine, Failure, Bone marrow, Myelocyte, 8-K, Toxic shock syndrome, Drug Quality and Security Act, Survival, Lymphocyte, IND, KSPI, Fine chemical, Pharmaceutical industry, Risk management, Gemtuzumab ozogamicin, Bayer

PALO ALTO, Calif., Dec. 11, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced a poster presentation of preclinical data of Vincerx’s proprietary payload and linker technology and VIP943, the Company’s internalizing ADC targeting CD123, at the 64th American Society of Hematology (ASH) Annual Meeting 2022.

Key Points: 
  • VIP943 combines the unique payload class of kinesin spindle protein inhibitors (KSPi) with a proprietary legumain-cleavable linker.
  • “I am truly excited about the preclinical results for VIP943 and our proprietary payload and linker technology presented at ASH,” said Ahmed Hamdy, M.D., Chief Executive Officer of Vincerx.
  • The in vivo AML mouse model results also showed improved efficacy and survival for VIP943 in combination with venetoclax and azacitidine.
  • Forward-looking statements speak only as of the date hereof, and Vincerx disclaims any obligation to update any forward-looking statements.

Ajax Therapeutics Presents Preclinical Data on AJ1-10502, a Next Generation Type II JAK2 Inhibitor, at the American Society of Hematology Annual Meeting

Retrieved on: 
Monday, December 12, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Health Technology, Clinical Trials, Therapy, Pancreatic serous cystadenoma, Spleen, MD, Poster, Doctor of Philosophy, Drug discovery, Society, Research, MPN, Patient, Translational research, MSK, Ajax, Myeloproliferative neoplasm, Memorial Sloan Kettering Cancer Center, Type, Type 2, Disease, Reticulocyte, JAK2, Bone marrow, Senior, Computational chemistry, Hematocrit, Secondary research, ASH, Pharmaceutical industry, Primary myelofibrosis, Leukemia

In preclinical studies, investigational Type II JAK2 inhibitors have been shown to overcome disease persistence to ruxolitinib and, most significantly, reduce mutant JAK2 allele burden that drives MPN disease progression.

Key Points: 
  • In preclinical studies, investigational Type II JAK2 inhibitors have been shown to overcome disease persistence to ruxolitinib and, most significantly, reduce mutant JAK2 allele burden that drives MPN disease progression.
  • Were very encouraged by the first preclinical data on our Type II JAK2 inhibitor program being presented today at the ASH Annual Meeting, said Craig E. Masse, PhD, Senior Vice President, Discovery Research at Ajax Therapeutics.
  • This data supports our findings that Type II JAK2 inhibitors can significantly reduce the mutant allele burden that drives MPNs which is not observed with Type I JAK2 inhibitors, such as ruxolitinib.
  • Ajax Therapeutics , Inc. is pursuing uniquely selective approaches to develop novel first-in-class therapeutics for myeloproliferative neoplasms (MPNs), including Myelofibrosis.

Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting

Retrieved on: 
Sunday, December 11, 2022
Biotechnology, Technology, Health, General Health, Pharmaceutical, Oncology, Other Technology, Research, Genetics, Science, Clinical Trials, Genome, SCD, Sickle, Sickle cell trait, B cell, AS, AA, Food, Ernest, Sickle cell disease, Poster, HBS, Society, Patient, DNA, Gene editing, Knowledge, Disease, HBA, FDA, Stem cell, Reticulocyte, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Bio, SS, Bone marrow, Safety, CRISPR, Blood, Health, HSC, Gene, ASH, RNA, Graphite, HDR, Mutation, Vaccine

The novel single-cell RNA sequencing method that we developed will help us determine initial gene editing outcomes in patients treated with nula-cel, providing important preliminary information about the potential efficacy of the investigational therapy.

Key Points: 
  • The novel single-cell RNA sequencing method that we developed will help us determine initial gene editing outcomes in patients treated with nula-cel, providing important preliminary information about the potential efficacy of the investigational therapy.
  • Based on this knowledge, Graphite Bio scientists sought to develop a single-cell RNA sequencing method that could measure gene editing outcomes in reticulocytes.
  • These data support the use of this method to determine initial gene editing outcomes in patients treated with nula-cel in order to support the clinical development of this investigational therapy.
  • Graphite Bio is a clinical-stage, next-generation gene editing company driven to discover and develop cures for a wide range of serious and life-threatening diseases.

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 4, 2022
MDS, Woman, Intellectual property, U.S. Securities and Exchange Commission, Risk, Lists of diseases, Disorder, Part, Trial of the century, GLOBE, Iron-deficiency anemia, TI, Hypertensive emergency, Private Securities Litigation Reform Act, Microdeletion syndrome, SEC, DLT, Alkaline phosphatase, Growth, BSAP, Achievement, Security (finance), KROS, Research, MAD, Osteoporosis, Patient, European Hematology Association, Therapy, COVID-19, Company, Șaeș, MF, Safety, Reticulocyte, Anemia, Iron overload, Maintenance, Bone loss, Erythropoiesis, Protein, PAH, Ruxolitinib, HTB, Osteogenesis imperfecta, BMP, Thrombocytopenia, Cytopenia, SAE, Pharmaceutical industry, Medical imaging, Vaccine, Dietary supplement

LEXINGTON, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary, and musculoskeletal disorders with high unmet medical need, today provided a business update and reported financial results for the quarter ended June 30, 2022.

Key Points: 
  • We continued the positive momentum for our pipeline programs into the second quarter of 2022.
  • In May 2022, Keros announced preliminary topline data from the Phase 1 clinical study of KER-012 in healthy postmenopausal women.
  • Keros reported a net loss of $27.3 million in the second quarter of 2022 as compared to a net loss of $15.6 million in the second quarter of 2021.
  • Research and development expenses were $23.3 million for the second quarter of 2022 as compared to $10.0 million for the same period in 2021.

Corrected: Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition

Retrieved on: 
Monday, December 13, 2021
Therapy, Death, Platelet, ALK2, MDS, RBC, TI, Incidence, Haematopoiesis, LTB, KROS, Fatigue, Thrombopoiesis, The Witch: Part 1. The Subversion, Serum, American Society of Hematology, HTB, Research, Inflammation, Solar cycle 1, Nausea, Reticulocyte, Exposition, Disease, RS, Disclosure, Model, GLOBE, Lists of diseases, Acute myeloid leukemia, ASH, Treatment, Breathe Me, Erythropoiesis, Society, Diarrhea, Cohort, Pharmaceutical industry, Medical device, Medical imaging, Residential care, Anemia, Patient, Hematology

LEXINGTON, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that it presented additional data from its ongoing Phase 2 clinical trial of KER-050 in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (“MDS”), as well as preclinical data on the differentiated mechanism of action of KER-050 and its activity in cytopenia models, at the 63rd American Society of Hematology (“ASH”) Annual Meeting and Exposition, held in person and virtually December 11 through 14, 2021. In addition, Keros announced preclinical data evaluating ALK2 inhibition as a potential treatment option for anemia of inflammation.

Key Points: 
  • In addition, Keros announced preclinical data evaluating ALK2 inhibition as a potential treatment option for anemia of inflammation.
  • We believe these data support the potential of KER-050 as a treatment for multilineage cytopenias in MDS by potentially targeting multiple stages of hematopoiesis.
  • Enrollment was balanced approximately one-to-one between patients that did not have ring sideroblasts (non-RS) and patients that have ring sideroblasts (RS positive).
  • ET, to discuss the additional results from the ongoing Phase 2 clinical trial of KER-050 presented at the 2021 ASH Annual Meeting and Exposition.